Figure 5.

Tumors with oncomorphic TP53 are more resistant to chemotherapy than patients with loss of function (LOF) or unclassified mutations. Rates of platinum resistance among The Cancer Genome Atlas (TCGA) cohort and a validation cohort from the University of Iowa. Number of patients (n) are noted in the plot. (B) The most common TP53 mutations were expressed in a cell line (SKOV3, p53 null) to examine the ability of oncomorphic p53 mutant proteins to cause chemoresistance to cisplatin or taxol. Western blot images are combined from two separate gels (demarked by the gray lines separating lanes from different gels). (C) Clonogenic survival of cells stably expressing various TP53 mutant proteins after 48 h treatment with 1 μM cisplatin (Cis) or 10 nM taxol (Tax). ^*P<0.05 vs. empty vector (EV) with the same treatment.